Bronchiectasis Severity Index

The Bronchiectasis Severity Index is a prognostic tool that stratifies patients by risk of exacerbations, hospitalization, and mortality based on clinical, microbiologic, and radiologic variables.

Age, years
< 50050-69+270-79+480++6
BMI
18.5-25026-29030 or more0< 18.5+2
FEV1 % predicted
> 80050-80+130-49+2< 30+3
Hospital admission before study
No0Yes+5
Exacerbation before the study
001-203 or more+2
Pseudomonas colonization
No0Yes+3
Colonization w/ other organisms
No0Yes+1
Radiologic severity: > 3 lobes involved or cystic bronchiectasis
No0Yes+1

Indications for Use

Used to risk‑stratify adults with CT‑confirmed bronchiectasis to guide follow‑up intensity and need for long‑term therapies. Predicts mortality, hospitalisation, exacerbation frequency, lung‑function decline and quality‑of‑life impairment with high accuracy (AUC 0.80–0.88) 1 [Level I evidence]; validated across multiple cohorts 2 [Level II evidence]. Helps identify high‑risk patients for aggressive airway clearance, antibiotic strategies and closer monitoring.

Insights & Cautions

Stratifies risk of mortality, hospitalisation and exacerbations using factors such as age, FEV1, prior exacerbations/hospitalisations, Pseudomonas colonisation and radiological extent, with strong validation (AUC 0.80–0.88 for mortality/hospitalisation) 1 [Level I evidence]. Cautions: may overestimate risk in some cohorts, excludes NTM, and should not replace clinical judgement; comorbidities (BACI) add prognostic value 2 [Level II evidence].